Unlike immune checkpoint inhibitors that aim to reverse the exhaustion state of T cells, the TLR9 agonist CpG combined with RT draws CD8+ T cells expressing markers associated with activation and proliferation into the tumor. Here, TLR9 is linked to neoplasm.